New Bone-Building Drug Promising Against Prostate Cancer

Monoclonal antibody denosumab counters effects of hormone therapy, study finds

By Ed Edelson
HealthDay Reporter

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Animal Bites • Ankylosing Spondylitis • Anterior Cruciate Ligament Repair More... Related Healthscout Videos Optimistic Healing Replacing Worn Out Wrists Cancer Treatment for Any Size Fever Kills Cancer More... Related Animations • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction • Osteoporosis Basics More... Related Drug Information • Cialis • Epogen • Flomax • Iressa More... Related News Articles • Switch to 'Light' Cigarettes Makes Quitting Tougher • Drug Could Help Treat Small HER2-Positive Breast Tumors • Trauma Deadlier for Kids Without Insurance • Low Cholesterol May Help Prevent Cancer More...

TUESDAY, Aug. 11 (HealthDay News) -- A new bone-building drug has worked well in a trial of men whose bones were weakened by the hormone therapy they were taking for prostate cancer, researchers report.

The drug, denosumab (Prolia), is a monoclonal antibody that Amgen Inc. hopes to market for fracture prevention, not only in men with prostate cancer but also for postmenopausal women who are taking hormone therapy for breast cancer. An advisory panel of the U.S. Food and Drug Administration is scheduled to meet this week to consider the Amgen application.

Text Continues Below

---

Results of the trial, reported online Aug. 11 in advance of publication in the Aug. 20 issue of the New England Journal of Medicine, will be part of the evidence submitted to the FDA panel. Anywhere from one-third to one-half of the 2 million American men receiving hormone-blocking therapy as treatment for prostate cancer are potential users of denosumab, said study author Dr. Matthew R. Smith, director of genitourinary medical oncology at Massachusetts General Hospital.

Denosumab blocks the activity of a molecule that causes destruction of bone cells. It thus counters the bone loss that results from lack of hormones, both male and female. The drug is given by intravenous injection, just once every six months.

The prostate cancer study was pioneering because "there have been no prior, large-scale fracture-preventing studies in men," Smith said. It enrolled more than 900 men being treated at 156 medical centers in the United States and Europe.

Over 24 months, bone density increased 5.6 percent in men who got denosumab and decreased 1 percent in men given a placebo, the researchers found. The 36-month incidence of spinal fractures was 1.5 percent among those receiving denosumab, while it was 3.9 percent among those given placebo.

Page:  1 | 2 | Next >>